Vertex Pharmaceuticals (NASDAQ: VRTX) might be one of those special cases. Should you buy Vertex stock hand over fist before ...

New facility to support advancements in molecular diagnostics, rare disease research, and industrial microbiology ...

But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...

PRNewswire Bengaluru Karnataka [India] January 16 Bengaluru-based biotechnology startup CrisprBits Private Limited has ...

In a world grappling with an ever-evolving geopolitical crisis, fostering cross-pollination of ideas, research, and policies ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

Colossal, a leading biosciences company working to combat environmental dangers and revive extinct species, has reached a new ...

While such predictions remain speculative, developments in AI over the next few years are easier to foresee. So, what transformative changes can we expect from AI in the year 2025 and beyond?